#Scinai Immunotherapeutics #Israel #Jerusalem #CDMO #BIO-Europe Spring

Scinai Immunotherapeutics Showcases Expanded CDMO and Immunology Pipeline at BIO-Europe Spring 2026

Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical firm making strides in inflammation and immunology therapeutics, has announced its participation in BIO-Europe Spring 2026 from March 23-25 in Lisbon, Portugal. This event marks the company's first major international conference since its recent acquisition of Recipharm Israel and strategic collaboration with Recipharm, signifying a substantial expansion of its development and manufacturing capabilities.

The Scinai delegation will be led by CEO Amir Reichman, along with key team members Solomon Gahtan and Dr. Helen Domeshek, who will represent the company’s CDMO subsidiary, Scinai Biopharma Services Ltd. They plan to engage with pharmaceutical and biotechnology firms, investors, and potential clients to promote Scinai's innovative R&D pipeline, as well as its integrated CDMO offerings.

A Differentiated Integrated CDMO Platform

Through Scinai Biopharma Services Ltd., Scinai offers a unique integrated CDMO platform that supports biotechnology and pharmaceutical companies from early development stages to commercial production. The core of this model lies in three strategic pillars: 1) a cGMP biologics development and manufacturing site in Jerusalem, 2) a cGMP small-molecule API development and manufacturing site located in Yavne—recently acquired from Recipharm, and 3) a strategic commercial collaboration with Recipharm.

This well-structured approach positions Scinai as a distinctive partner capable of bridging early-stage innovation with global commercial manufacturing. The collaboration with Recipharm is set to enhance Scinai’s capabilities by providing access to more resources and advanced technologies via subcontracting arrangements. It facilitates a seamless transition for clients from preclinical to commercial production while aligning quality and tech transfer standards, thereby mitigating execution risk and shortening timelines.

At BIO-Europe Spring, Scinai will emphasize its commitment to flexible, high-quality development and manufacturing solutions that offer a clear and scalable pathway toward commercialization for its clients.

Advancing a Robust Pipeline of Immunotherapies

Additionally, Scinai will highlight its expanding pipeline of innovative antibody-based therapies specifically targeting autoimmune and inflammatory diseases, with a strong focus on dermatology. This pipeline comprises assets that have been licensed from renowned institutions including the Max Planck Society, University Medical Center Göttingen, and PinCell S.r.l.

The company is keen on establishing strategic partnerships, as well as co-development collaborations and licensing opportunities with both pharmaceutical and biotechnology firms to propel its pipeline forward.

As CEO Amir Reichman stated, "BIO-Europe Spring marks an important milestone for Scinai as we present our expanded capabilities following the Recipharm transaction. We are uniquely positioned to partner with biotech and pharma companies across the full lifecycle of their products, from early-stage development through clinical and into commercial manufacturing, while also advancing a differentiated pipeline of immunology therapeutics. We look forward to engaging with partners who are seeking both innovation and execution."

About Scinai Immunotherapeutics

Scinai Immunotherapeutics Ltd. is dedicated to advancing innovative immunology therapies. The company has developed a promising pipeline of therapeutic candidates, in collaboration with esteemed institutions such as the Max Planck Society and PinCell S.r.l. Scinai also operates Scinai Biopharma Services Ltd., a CDMO that provides comprehensive development and manufacturing services to the biotech and pharma sectors.

For further details, visit www.scinai.com.